Industry-friendly reimbursement vital in Japan
This article was originally published in Clinica
Executive Summary
The availability of breakthrough medical technologies in Japan - the C2 category of product - could be improved by adopting reimbursement policies that are more responsive to innovation, industry believes. Industry and patients are currently impeded by the fact that C2 products are ineligible for reimbursement for at least two years after receipt of regulatory approval.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.